Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 1.00 |
| ▸ | MPC2 | O95563 | 2/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18541511 | 1.00 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL18541485 | 1.00 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL29376450 | 1.00 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6931416 | 0.91 | PPARG (0.83) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6930322 | 0.90 | PPARG (0.82) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL23836847 | 0.89 | PPARG (0.83) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL937521 | 0.89 | PPARG (0.83) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL16075634 | 0.89 | PPARG (0.80) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL16075636 | 0.89 | PPARG (0.80) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL16075632 | 0.89 | PPARG (0.80) | PPARGMPC2CYP2C8CYP2C9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203433-B1 | 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes | METABOLIC SOLUTIONS DEV CO LLC (US) | 2012-10-31 | — | — | EP | claimed |
| US-8067450-B2 | Thiazolidinedione analogues for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-11-29 | — | — | US | claimed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | claimed |
| EP-2203433-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | Metabolic Solutions Development Company (US) | 2010-07-07 | — | — | EP | claimed |
| WO-2009038681-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2009-03-26 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024107862-A1 | ORAL DOSAGE FORMS FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | VIKING THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11918569-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | POXEL SA (FR) | 2024-03-05 | — | — | US | disclosed |
| US-20230210825-A1 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | CIRIUS THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210825-A1 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | CIRIUS THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230013627-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| WO-2010105048-A9 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010105048-A1 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| EP-2203433-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | Metabolic Solutions Development Company (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009038681-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038681-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | AGTR2, ADRB1, ADRB3 | PPARG 42/4885MPC2 989/4885CYP2C8 850/4885 |
| US-20230210825-A1 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | ACE, DPP4, ACE2 | PPARG 19/4885MPC2 223/4885CYP2C8 548/4885 |
| US-20230013627-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | FABP1, HNF4A, PPARD | PPARG 6/4885MPC2 153/4885CYP2C8 524/4885 |
| US-11918569-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | SLC5A2, PPARD, DPP4 | PPARG 10/4885MPC2 636/4885CYP2C8 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.